Propagator Ventures

Anders Gudmund Frøseth serves as General Partner and Chairman. He is joined by General Partner and CEO Eirik Talleraas, the former Head of UNDP Norway, and General Partner Andreas Luotonen Emblem. The partnership makes decisions collaboratively, supported by a network of scientific advisers that helps identify and evaluate technically complex startups.

Propagator relies on a curated network of scientific domain experts to surface early-stage opportunities, particularly in fields like quantum computing, computational medicine, and advanced materials. Frøseth’s mentorship at the Creative Destruction Lab extends that network into North American deep-tech ecosystems. The firm then co-invests alongside specialist VCs such as Radical Ventures, which further validates technical due diligence.

Propagator Ventures is structured as a specialist venture capital firm, not a single family office, although its initial capital came from Anders Frøseth’s family wealth tied to Laerdal Medical. The firm raises funds open to qualifying external LPs — Fund 2 remains open — and operates at arm’s length from the Laerdal operating business and its philanthropic foundations.

Propagator does not publish a formal exclusion list, but its investment thesis explicitly gravitates toward hard-science and engineering breakthroughs. Consumer internet, enterprise SaaS without a hardware or deep-tech component, and traditional life sciences services fall well outside the firm’s four stated investment areas: computational medicine, future compute, new materials, and robotics.

Propagator makes direct equity investments into early-stage companies. There is no public record of the firm committing capital as an LP into third-party venture funds. Its co-investment relationships — for example with Radical Ventures on Axiomatic AI — are executed as direct co-investments alongside other VCs in specific rounds.

Anders Gudmund Frøseth is an heir to the Laerdal Medical fortune. Laerdal Medical, headquartered in Stavanger, Norway, is the global market leader in simulation-based medical training, emergency airway management, and defibrillation. The family’s wealth seeded Propagator Ventures and continues to anchor its patient-capital posture.

The Laerdal Foundation for Acute Medicine and Laerdal Global Health are philanthropic entities tied to the Laerdal Group, not to Propagator Ventures. They operate independently, funding research and programs in maternal and newborn health. Propagator Ventures does not manage or direct those philanthropic assets, though the family’s broader focus on sustainable-development goals is visible in the UN Global Compact membership.